November 6th 2023
Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.
Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.
October 30th 2023
Explore the case of a 67-year-old patient with recurrent endometrial cancer, highlighting the importance of MMR testing, NGS, and emerging treatment options in today's landscape.
Dive into the evolving landscape of endometrial cancer, including rising incidence, classification, racial disparities, and emerging modalities, as discussed by experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD.
August 10th 2023
The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.
An overview of ongoing research in the endometrial cancer treatment space.
August 3rd 2023
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.
July 27th 2023
Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.
The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.
July 20th 2023
Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.
A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.
July 13th 2023
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
July 6th 2023
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.
June 29th 2023
Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.
A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.
November 22nd 2022
Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.
November 15th 2022
Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.